Stockholm - Delayed Quote SEK

Elekta AB (publ) (EKTA-B.ST)

49.96
+0.72
+(1.46%)
At close: May 9 at 5:29:36 PM GMT+2
Loading Chart for EKTA-B.ST
  • Previous Close 49.24
  • Open 49.60
  • Bid 49.90 x --
  • Ask 49.94 x --
  • Day's Range 49.54 - 50.35
  • 52 Week Range 44.50 - 88.85
  • Volume 959,689
  • Avg. Volume 1,333,836
  • Market Cap (intraday) 19.089B
  • Beta (5Y Monthly) 1.08
  • PE Ratio (TTM) 18.37
  • EPS (TTM) 2.72
  • Earnings Date May 28, 2025
  • Forward Dividend & Yield 2.40 (4.87%)
  • Ex-Dividend Date Mar 6, 2025
  • 1y Target Est 67.07

Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software. In addition, the company offers Elekta ONE, a software suite of multiple Elekta solutions. Further, it provides brachytherapy products, including Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Elekta Xoft Axxent, and electronic brachytherapy systems; Elekta Geneva, an applicator for cervical cancer patients; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Venezia applicator that enables the oncologist to treat locally advanced cervical cancer. Additionally, the company offers neurosurgery products, such as Leksell Vantage Stereotactic System for intracranial neurosurgery. Furthermore, it provides Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

elekta.com

4,541

Full Time Employees

April 30

Fiscal Year Ends

Recent News: EKTA-B.ST

View More

Performance Overview: EKTA-B.ST

Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

EKTA-B.ST
16.61%
OMX Stockholm 30 Index (^OMX)
1.38%

1-Year Return

EKTA-B.ST
34.43%
OMX Stockholm 30 Index (^OMX)
5.41%

3-Year Return

EKTA-B.ST
12.82%
OMX Stockholm 30 Index (^OMX)
27.89%

5-Year Return

EKTA-B.ST
36.93%
OMX Stockholm 30 Index (^OMX)
56.66%

Compare To: EKTA-B.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: EKTA-B.ST

View More

Valuation Measures

As of 5/9/2025
  • Market Cap

    19.09B

  • Enterprise Value

    24.37B

  • Trailing P/E

    18.37

  • Forward P/E

    12.00

  • PEG Ratio (5yr expected)

    1.24

  • Price/Sales (ttm)

    1.07

  • Price/Book (mrq)

    1.77

  • Enterprise Value/Revenue

    1.36

  • Enterprise Value/EBITDA

    8.44

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.80%

  • Return on Assets (ttm)

    3.60%

  • Return on Equity (ttm)

    9.82%

  • Revenue (ttm)

    17.88B

  • Net Income Avi to Common (ttm)

    1.04B

  • Diluted EPS (ttm)

    2.72

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.58B

  • Total Debt/Equity (mrq)

    81.83%

  • Levered Free Cash Flow (ttm)

    804.37M

Research Analysis: EKTA-B.ST

View More

People Also Watch